MULTI EXPRESS DEFENDER VONCERT - ELI LILLY & CO/NOVO-NORDISK B/BRISTOL-MYERS SQUIBB/PFIZER INC MULTI EXPRESS DEFENDER VONCERT - ELI LILLY & CO/NOVO-NORDISK B/BRISTOL-MYERS SQUIBB/PFIZER INC Stock
Certificat
F49000
DE000VD7CEJ3
| Real-time Borsa Italiana 03:53:44 2024-07-05 EDT | ||
| 99.3 EUR | +0.10% |
|
| Current month | -1.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 99.3 | +0.10% |
| 24-07-04 | 99.2 | +0.40% |
| 24-07-03 | 98.8 | -1.00% |
| 24-07-02 | 99.8 | -0.50% |
| 24-07-01 | 100.3 | 0.00% |
Real-time Borsa Italiana
Last update July 05, 2024 at 03:53 am
More quotesStatic data
| Product type | Other Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| F49000 | |
| ISIN | DE000VD7CEJ3 |
| Date issued | 2024-06-13 |
| Maturity | 2026-12-11 (890 Days) |
| Parity | 1 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 100.5 € |
|---|---|
| Lowest since issue | 98.7 € |
| Spread | 1 € |
| Spread % | 1.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.06
USD
Average target price
53.19
USD
Spread / Average Target
+32.79%
- Stock Market
- Certificates
- F49000 Certificat
